Aktionsplan Acasti Pharma Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
| Выручка |
0.000196 |
| EBITDA |
-0.031 |
| Число акций ао |
0.00744 млрд |
| P/S |
461 |
| P/BV |
42.59 |
| EV/EBITDA |
-13.87 |
| Цена ао |
3.4 |
| ISIN |
CA00430K8730 |
| Сайт |
https://www.acastipharma.com
|
| Валюта |
usd |
| IPO date |
2011-05-06 |
| Sector |
Health Care |
| Industry |
Pharmaceuticals |
| Валюта отчета |
usd |
| Preisänderung pro Tag: |
+1.33% (3) |
| Preisänderung pro Woche: |
-2.56% (3.12) |
| Preisänderung pro Monat: |
+24.08% (2.45) |
| Preisänderung über 3 Monate: |
+6.67% (2.85) |
| Preisänderung über sechs Monate: |
-10.59% (3.4) |
| Preisänderung pro Jahr: |
+14.72% (2.65) |
| Preisänderung über 3 Jahre: |
+34.51% (2.26) |
| Preisänderung über 5 Jahre: |
+62.57% (1.87) |
| Preisänderung seit Jahresbeginn: |
+36.94% (2.22) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
26141.39 |
1 |
| P/BV |
0.3825 |
10 |
| P/E |
0 |
0 |
| EV/EBITDA |
-0.088 |
0 |
| Gesamt: |
|
3.88 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
-53.62 |
0 |
| ROE, % |
-62.44 |
0 |
| Gesamt: |
|
1.17 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Gesamt: |
|
0 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
0.0306 |
10 |
| Gesamt: |
|
9.6 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
-97.69 |
0 |
| Rentabilität Ebitda, % |
-27.09 |
0 |
| Rentabilität EPS, % |
-87.03 |
0 |
| Gesamt: |
|
0 |
|
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Mr. Prashant Kohli |
CEO & Director |
358.41k |
1972 (52 Jahr) |
| Dr. R. Loch MacDonald M.D., Ph.D. |
Member of Scientific Advisory Board & Chief Medical Officer |
N/A |
1962 (62 Jahr) |
| Mr. Amresh Kumar Ph.D. |
VP of Program Management |
N/A |
1980 (44 Jahr) |
| Mr. Robert J. DelAversano CPA |
VP of Finance and Principal Financial & Accounting Officer |
N/A |
1972 (52 Jahr) |
| Ms. Carrie D'Andrea |
VP of Clinical Operations |
|
1972 (52 Jahr) |
